London, United Kingdom – Newsfile Corp. – May 14, 2025 – Gorilla Technology Group Inc. (NASDAQ: GRRR) (“Gorilla” or the “Company”), a global solution provider in Security Intelligence, Network Intelligence, Business Intelligence and IoT technology, is pleased to announce the appointment of Bruce Bower as Chief Financial Officer (CFO), effective 1 June 2025.
Mr. Bower brings a wealth of experience in strategic financial management, capital raising and corporate governance. Since joining Gorilla as Interim CFO in September 2024, he has played a pivotal role in restructuring the Company’s finance department, streamlining operations, and enhancing Gorilla’s financial oversight and internal controls. Under Bruce’s leadership, the Company has achieved full compliance with the Sarbanes-Oxley Act (SOX) and resolved any previously disclosed material weaknesses, while continuing to secure significant partnerships.
“Bruce has been instrumental in driving Gorilla’s financial strategy during a transformative period. We successfully navigated a complex landscape, optimised capital structures that drove profitability in key growth areas and accelerated our position in the market as a global innovator of AI solutions in smart infrastructure, energy and security,” said Jay Chandan, Chairman & CEO of Gorilla Technology Group. “Under Bruce’s leadership, we have successfully enhanced our financial reporting and governance frameworks, reinforcing our commitment to the highest standards of corporate integrity.”
“I am proud to continue the important mission that Gorilla has set forth,” said Mr. Bower. “While we have made great progress as a team, I have more conviction than ever that our greatest opportunity lies ahead. I look forward to continuing to deliver on our growth plans as we collectively work to achieve Gorilla’s innovative vision of the future.”
About Gorilla Technology Group Inc. Headquartered in London U.K., Gorilla is a global solution provider in Security Intelligence, Network Intelligence, Business Intelligence and IoT technology. We provide a wide range of solutions, including, Smart City, Network, Video, Security Convergence and IoT, across select verticals of Government & Public Services, Manufacturing, Telecom, Retail, Transportation & Logistics, Healthcare and Education, by using AI and Deep Learning Technologies.
Our expertise lies in revolutionizing urban operations, bolstering security and enhancing resilience. We deliver pioneering products that harness the power of AI in intelligent video surveillance, facial recognition, license plate recognition, edge computing, post-event analytics and advanced cybersecurity technologies. By integrating these AI-driven technologies, we empower Smart Cities to enhance efficiency, safety and cybersecurity measures, ultimately improving the quality of life for residents.
For more information, please visit our website: Gorilla-Technology.com.
Investor Relations Contact: Dave Gentry RedChip Companies, Inc. 1-407-644-4256 GRRR@redchip.com
The issuer is solely responsible for the content of this announcement.
Exploring the Risks and Opportunities of AI Applications in Cybersecurity
HONG KONG SAR – Media OutReach Newswire – 14 May 2025 – Co-organised by Cyberport and the Hong Kong Cybersecurity Professionals Association, the “AI x Cybersecurity Forum” took place today at Cyberport. Under the theme “Navigate the Future of AI-Powered Cybersecurity,” the forum brought together over 400 government representatives, cybersecurity experts, leaders from academia and the technology industry to discuss the challenges that Artificial Intelligence (AI) poses to cybersecurity, regulatory policies, and data protection, as well as how AI-driven cybersecurity measures can more effectively combat emerging cyber threats.
Chenhong Mu, Deputy Director of Information Centre, Liaison Office of the Central People’s Government in the HKSAR (fifth from the right, front row), Ir Tony Wong, JP, Commissioner for Digital Policy, Digital Policy Office (fourth from the left, front row), Dr Rocky Cheng, Chief Executive Officer of Cyberport (fifth from the left, front row), Prof Cao Jiannong, Vice President, Hong Kong Cybersecurity Professional Association (third from the left, front row), and other guests jointly officiated the opening of the “AI x Cybersecurity Forum”.
Ir Tony Wong, JP, Commissioner for Digital Policy, Digital Policy Office, stated, “Artificial intelligence is rapidly evolving. As we embrace the broader landscape of technological development, it is essential to integrate cybersecurity with innovative technologies to address the challenges of this new era. The government is committed to promoting the application of AI while strengthening governance. Through the ‘Ethical Artificial Intelligence Framework’ and the recently announced ‘Guidelines for Generative Artificial Intelligence Technology and Applications in Hong Kong’, we provide practical guidance for developers and users, aiming to balance innovation, application, and responsibility in AI. We look forward to collaborating with various sectors to develop and apply AI technology in a safe and responsible manner, fostering the widespread advancement of AI in Hong Kong.”
Dr Rocky Cheng, Chief Executive Officer of Cyberport, stated, “As the digital era rapidly advances, cybersecurity challenges are growing increasingly severe. While the widespread adoption of AI introduces new cyber threats, it also enhances our defensive capabilities. As Hong Kong’s digital tech hub and AI accelerator, Cyberport is committed to advancing cybersecurity development. By nurturing cybersecurity start-ups and collaborating with various sectors to launch different activities and training programmes, we aim to raise cybersecurity awareness among businesses and individuals. At the same time, we are bringing together leading technology security companies from the Mainland and overseas to promote relevant technological innovation and facilitate technical exchanges, all with the goal of building a comprehensive cybersecurity ecosystem. Moving forward, we will continue partnering with industry leaders to harness AI for cybersecurity solutions, building a safer and smarter Hong Kong.”
The forum featured insights from several leaders across various sectors, including Prof Li Hui, Emeritus Professor, Peking University, Adjunct Professor, Fuyao University of Science and Technology, Raymond Lam, Chief Superintendent of Police, Cyber Security and Technology Crime Bureau, Hong Kong Police Force, and Prof Wang Cong, Professor and Head, Department of Computer Science, City University of Hong Kong. They discussed the latest challenges and developments in cyber defence and attack. Prof Li Hui shared his views on cybersecurity and the challenges of developing large AI models. Meanwhile, Raymond Lam pointed out that the Cyber Security and Technology Crime Bureau is currently using AI to analyse the authenticity of images and videos generated by deepfake technology, which also serve as evidence in police investigations. The bureau also collaborates with research experts and employs a government-business-academia-research ecosystem to combat cybercrime and strengthen cyber defence capabilities.
The forum featured multiple panel discussions on how governments and institutions can improve cybersecurity policies in light of the growing prevalence of AI applications, how the banking and healthcare sectors can balance security with innovation, and how to leverage AI to enhance information protection. One notable discussion, moderated by Stanley Wong, Chief Information Security Officer at Cyberport, focused on “AI Against AI”. In this session, technology leaders examined innovation solutions, such as AI threat models, to prevent and mitigate emerging cyber attacks driven by AI, thereby protecting company assets. Another panel moderated by Dr Crystal Fok, Director of AI Application at Cyberport, brought together cybersecurity experts from the Hong Kong Monetary Authority, the Hong Kong Hospital Authority, and the Digital Policy Office to explore how to leverage AI to enhance information protection. They emphasized the importance of collaboration among stakeholders to foster a balance between innovation and governance. The discussions also explored how stakeholders can build more resilient digital governance frameworks through comprehensive security concepts, enhanced education, and risk management.
As Hong Kong’s digital tech hub and AI accelerator, Cyberport is committed to building a robust and secure AI ecosystem. Following its first collaboration with international organisations in February to host the “AI Safety, Trust, and Responsibility” Forum, which promoted the joint effort to build a trustworthy and responsible AI ecosystem, this forum once again demonstrated Cyberport’s commitment to advancing secure and trustworthy AI development. Notably, Cyberport has achieved significant milestones in building the AI ecosystem, including the launch of Hong Kong’s largest Artificial Intelligence Supercomputing Centre (AISC) last year, and the establishment of the AI Lab as a platform for technology demonstrations, and commercial applications, fully supporting AI start-ups from R&D to market entry. Furthermore, the HKSAR Government has allocated HK$3 billion to Cyberport to implement a three-year AI Subsidy Scheme, which includes subsidising eligible entities on the use of computing power of the AISC to continuously inject impetus into the local AI development.
Currently, Cyberport brings together around 400 AI and data science start-ups, attracted several leading AI enterprises, and has facilitated collaborations with major tech firms. By leveraging their expertise in computing power development, large model construction, algorithms, data science, and industry applications, Cyberport supports innovation, research, and application across various segments of the AI ecosystem, driving industrial development and helping position Hong Kong as an international hub for the AI industry. Hashtag: #Cyberport
The issuer is solely responsible for the content of this announcement.
About Hong Kong Cyberport
Wholly owned by the Hong Kong Special Administrative Region (HKSAR) Government, Cyberport is Hong Kong’s digital tech hub and AI accelerator, with a vision to empower industry digitalisation and intelligent transformation, to promote digital economy and AI development, and to foster Hong Kong to be an international AI, innovation and technology (I&T) hub. Cyberport gathers over 2,200 companies, including 5 listed companies and 7 unicorns. One-third of onsite companies’ founders come from 26 countries and regions, while Cyberport companies have expanded to over 35 global markets.
Cyberport, with Hong Kong’s largest AI Supercomputing Centre and AI Lab as the engine, has been building the AI ecosystem with industry-leading AI companies and around 400 AI and data science start-ups. Through development of tech clusters, namely AI, data science, blockchain and cybersecurity, Cyberport empowers industries across smart city and government, banking and finance, digital entertainment, culture and tourism, healthcare, education and training, property management, construction, transportation and logistics, green environment and more, while hosting Hong Kong’s largest FinTech community. Commissioned by the HKSAR Government, Cyberport has implemented proof-of-concept and sandbox schemes, subsidisation for digital tech adoption, industry tech training and start-up incubation, to drive technology R&D, translation and commercialisation, thus propelling digital transformation and intelligent upgrade across industry and society.
Also as Hong Kong’s key incubator, Cyberport supports entrepreneurs with funding and office space, extensive networks of enterprises, investors, technology corporations and professional services for business growth and expansion to Mainland China and overseas markets, all-round facilitation for landing in Hong Kong, talent attraction and cultivation, ready as a launchpad to take start-ups in any stages of development to the next level. For more information, please visit https://www.cyberport.hk/en
KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 14 May 2025 – Ai Mediq SA today officially launched Intermittent Hypoxia-Hyperoxia Therapy (IHHT), a science-backed, non-invasive breathing therapy that strengthens the cardiovascular system at its cellular core. By training the body to adapt to fluctuating oxygen levels, IHHT enhances heart function, improves metabolic efficiency, supports cognitive health, and reduces inflammation.
IHHT cycles between low-oxygen (hypoxia) and high-oxygen (hyperoxia) breathing intervals, acting like “interval training for your cells.” It optimizes oxygen use, lowers inflammation, and boosts resilience without the risks associated with continuous hypoxia.
Rooted in oxygen-sensing molecular mechanisms, a Nobel Prize-winning discovery, IHHT triggers regenerative cellular processes. Devices like ReOxy® and HIBERG® use Self-Regulated Treatment (SRT) technology to personalize sessions based on real-time data such as heart rate and oxygen saturation, ensuring optimal and safe results.
Clinical Evidence
A 2023 review published in Metabolites analyzed 16 clinical studies (https://www.mdpi.com/2218-1989/13/2/181), confirming IHHT’s benefits across cardiovascular, cognitive, and metabolic health:
Cardiac Rehabilitation: 15 sessions improved exercise tolerance, lipid profiles, and quality of life (Glazachev et al., 2017).
Cognitive Health: Elderly patients showed a 20% MoCA score improvement after IHHT (Serebrovska et al., 2019).
Metabolic Syndrome: IHHT reduced LDL cholesterol, inflammatory markers, and improved blood sugar control (Bestavashvili et al., 2021).
Geriatric Care: Combined therapy led to a 30% greater improvement in mobility and cognitive function (Bayer et al., 2017).
Ripple Effects of IHHT
Beyond the proven benefits, IHHT enhances cognitive function, supports metabolism and longevity, improves athletic recovery, and reduces systemic inflammation.
From Clinical Evidence to Real-World Application: ReOxy® and HIBERG®
Once reserved for elite athletes and clinical trials, IHHT is now accessible to both medical professionals and health-conscious individuals:
ReOxy® is a CE-certified medical device designed for clinical settings. It delivers fully automated IHHT protocols tailored to individual patients, making it ideal for cardiology, rehabilitation, and integrative medicine practices.
HIBERG® adapts the same core technology for personal use, offering guided breathing sessions to support recovery, stress relief, sleep, and energy balance. It’s a powerful wellness solution for anyone seeking performance and longevity.
Both devices are powered by SRT-Technology, ensuring personalised, safe, and effective treatment every session.
Hashtag: #AiMediqSA #IHHT
The issuer is solely responsible for the content of this announcement.
About Ai Mediq SA
Headquartered in Luxembourg, Ai Mediq SA develops advanced breathing therapies backed by clinical research. Its flagship innovations, ReOxy® and HIBERG®, bring cutting-edge, non-invasive solutions into everyday health practices.
BRUSSELS, BELGIUM – Newsaktuell – 14 May 2025 – Prof Dr Klemens Joos (56) has been back at the helm of the EUTOP Group as CEO since 13 May 2025. The background to this is an ambitious growth strategy up to 2035 for the EUTOP Group, which he founded in 1990 while studying business administration at the Ludwig Maximilian University (LMU) in Munich. Just one year after its foundation, the company had a representative office in Brussels. Today, the EUTOP Group has subsidiaries or representative offices in the capitals of all major European Union member states in addition to Brussels.
Prof Dr Klemens Joos photographed by Laurence Chaperon
Prof Dr Klemens Joos is also an honorary professor of ‘Business Administration – Political Stakeholder Management’ at the Technical University of Munich (TUM). Hashtag: #EUTOPGroup
The issuer is solely responsible for the content of this announcement.
WUZHISHAN, CHINA – Media OutReach Newswire – 14 May 2025 – May is a great season to experience the French romance. Nearly 20 members of the Wuzhishan Li & Miao Children’s Choir once again set off in central Hainan Island, China, for a cultural exchange in France.
From May 8 to 10, the Wuzhishan Li & Miao Children’s Choir once again set off in central Hainan Island, China, for a cultural exchange in France.
On the evening of May 9 (local time), nearly 300 guests lined up outside Café de la Danse, a theater in downtown Paris, to enjoy the show that highlighted the friendship between the two countries. When the Chinese and French versions of “Sing Wuzhishan to France” alternated, the performance reached its climax, and everyone could not help but clap along to the song. The event ended with “Auld Lang Syne.” Monica, a French audience member, expressed that she was highly impressed and thrilled about the people-to-people exchange.
The repertoire was co-prepared by the Wuzhishan Li & Miao Children’s Choir, Le Choeur des Polysons, La Chorale Chin’harmonie, and Association Vent d’Orient Vent d’Occident.
“Last May, we sang together to celebrate the 60 years of Sino-French diplomacy. Last October, Le Choeur des Polysons performed in Wuzhishan. Children bonded over music and gained a better understanding of each other’s cultures. Today, we reunited in Paris, and I am deeply touched.” Elisabeth Trigo, the head of the Le Choeur des Polysons, said.
Another phenomenal scene was the collaboration between Huang Hailin and Matthieu Lecoq. Hailin is an inheritor of Hainan’s intangible cultural heritage, the nose flute, which is a bamboo instrument of the Li ethnic group. Matthieu is a musician of the Opéra de Paris who uses the flute to demonstrate his love of the history and mythology of Wuzhishan. He stated, “It is a tremendous pleasure working with her for the first time and finding synergy between Chinese and Western music.”
This year marks the 50th anniversary of the establishment of diplomatic ties between China and the EU. The Publicity Department of the Wuzhishan Municipal Party Committee is one of the organizers of this visit event, the Wuzhishan Li & Miao Children’s Choir also visited the UNESCO headquarters, the Cinémathèque Française, and a primary school, not only observing the wonderful diversity of world heritage and experiencing France’s one-of-a-kind arts but also spreading excellent.
Hainan is blessed with abundant natural and cultural resources and has unique potential in adding ‘Hainan Tropical Rainforest and the Traditional Settlement of Li Ethnic Group’ to the UNESCO Heritage List. We hope that Hainan can further integrate resources and strengthen systematic protection and innovative development of intangible cultural heritage, said Wang Ying, Deputy Delegate of the Chinese Permanent Delegation to UNESCO.
The issuer is solely responsible for the content of this announcement.
Leaders from seven humanoid manufacturers convene with hardware experts to discuss the future of humanoid hardware standardization
VANDALIA, OHIO – Media OutReach Newswire – 14 May 2025 – Johnson Electric, a global leader in motion systems, hosted the inaugural 2025 Humanoid Roundtable on April 29 in Boston, MA, USA. The event brought together C-suite and technical executives in small to large humanoid manufacturers located across North America, Europe, and China.
Co-hosted by advanced technology experts, ESTAT Actuation, Netzer Precision, and IMSystems, the aim was to foster an open and informal discussion on the future of humanoid hardware standardization. Participants shared challenges, identified overlapping needs, and explored how shared standards might simplify integration and reduce costs. Top priorities included addressing recurring technical hurdles—such as motor-gearbox compatibility, connector reliability, and the lack of modular, off-the-shelf actuation systems.
“We found our hypothesis to be largely correct; in future humanoid platforms, differentiation will increasingly come from AI, training data, and application learning systems,” said Adam Stienecker, Director of Global Innovation at Johnson Electric.
That framing set the tone for a discussion that ranged from subsystem modularity to the broader need for scalable service infrastructure and commercialization strategies beyond the product itself. The challenges and priorities raised are now helping shape the focus of Johnson Electric’s follow-on event this September with A3, where the company will introduce its new joint solutions designed to reduce system cost and enable advanced functionality.
“There was a clear willingness to define what standards could look like—and to keep the conversation going. We’re looking forward to building on that momentum in September with A3, as plans are finalized.” said Carlos Richardson, roundtable emcee and Business Designer at Johnson Electric.
The 2025 Humanoid Roundtable is part of a broader industry effort to accelerate the path to scalable, serviceable, and commercially viable humanoid systems.
For interest related to humanoid joint systems, to speak into standardization, or to learn more, please contact the Johnson Electric team at innovation@johnsonelectric.com
Hashtag: #JohnsonElectric
The issuer is solely responsible for the content of this announcement.
About Johnson Electric
The Johnson Electric Group is a global leader in electric motors, actuators, motion subsystems and related electro-mechanical components. It serves a broad range of industries including Automotive, Smart Metering, Medical Devices, Business Equipment, Home Automation, Ventilation, White Goods, Power Tools, Lawn & Garden Equipment, and Warehouse Automation. The Group is headquartered in Hong Kong and employs more than 30,000 individuals in over 20 countries worldwide. Johnson Electric Holdings Limited is listed on The Stock Exchange of Hong Kong Limited (Stock Code: 179). For more information, visit johnsonelectric.com.
*********
This press release contains forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those projected due to a variety of factors, including but not limited to technological challenges, market conditions, and regulatory developments.
Positioned to Unlock M&A Value through U.S. Manufacturing Amidst Geopolitical Complexities and Specialty Portfolio
HONG KONG SAR – Media OutReach Newswire – 14 May 2025 – Bora Pharmaceuticals (TWSE: 6472) today announced its financial results and operational highlights for first quarter of 2025.
Quarterly Business and Financial Highlights
Fueled by expanded capacity and new dosage forms, Bora’s CDMO business delivered a record high quarter, up 52.4% YoY and 3.0% QoQ.
As part of Bora’s long-term strategic growth plan, the Company is moving forward with a phased investment of tens of thousands US dollars to unlock the untapped potential of Maple Grove facility. This build-out is designed to enhance capabilities in oral solid dose and sterile manufacturing, strengthening the ability to support customer demand and scale future programs.
Pharma Sales revenues rose 82.0% YoY based on reported unaudited monthly sales, driven by strong performance from the vigabatrin franchise, which includes three dosage forms. Notably, VIGAFYDE captured over 70% share in the new patient segment.
Due to the completion of Plymouth area decommissioning, consolidated revenues for 1Q25 was NT$4.48 billion, a NT$350 million reversal from the unaudited monthly disclosures, all of which was attributed to the pharma sales segment.
Despite margin pressure from partial maintenance shutdowns at the Maryland sterile injectable site in early January and softening demand for generic product dexlansoprazole (DLS), product mix improvement from growing specialty portfolio lifted gross margin from the low of 4Q24 to 42.2% in 1Q25. Tech transfer for 6 Upsher-Smith generic products to cost-competitive sites within Bora network remains on track, with full transfer expected by year-end to support further margin recovery.
EPS from continuing operations reached NT$26.54, reflecting NT$2.44 billion of net non-operating income from the divestment of Bora Biologics and recognition of losses of Tanvex Biopharm. However, the decommissioning of the Plymouth area negatively impacted EPS by NT$12.99, resulting in a reported EPS of NT$13.55. Share capital increased 0.4% during the quarter from employee stock option exercises and convertible bond conversions.
DLS competitors began exiting the market in early 2Q25 due to supply chain hiccups, creating new opportunities for Bora to increase share and drive recovery momentum.
The Group remains optimistic that its first quarter restructuring efforts will increase the long-term value of its recent acquisitions, including unlocking NT$600 million in capital in 2025. CDMO business growth will be further accelerated with strategic U.S.-based capability and capacity.
Mr. Bobby Sheng, Chairman of Bora Group, stated, “The first quarter is the continuation of critical integration and restructuring phase following multiple business and capacity acquisitions in 2024, laying a solid foundation for operational efficiency expansion. Following substantial investments in the U.S last year, we did observe significant pressure in the U.S. generics space during Q4. This prompted us to swiftly accelerate our integration efforts. At the same time, evolving client dynamics and market demand have only strengthened our conviction in the long-term value and strategic role of these assets. While the organizational streamlining, business separation, and product portfolio optimization undertaken to reflect operational realities have created near-term hurdles, we remain confident that these actions are essential to achieving optimal resource allocation and hence satisfactory return on assets. These efforts are necessary steps in the Company’s path toward sustainable mid to long-term growth.
The closure of Plymouth area was completed ahead of schedule during the quarter and the area has thus been reclassified as discontinued operation in our quarterly financial statements altogether. From an operational standpoint, Bora has discontinued 15 products in the U.S. generics market along with the restructure, with an additional 6 products transferred to more cost-efficient manufacturing sites within the Group. On the financial side, discontinued operation resulted in a negative impact of approximately NT$1.34 billion, including overhead, inventory and equipment write-downs as well as severance-related expenses. Looking ahead, Bora will advance its focus on high-value and complex dosage forms supported by over NT$5.0 billion cash on hand. At Maple Grove, 4 global pharmaceutical clients are currently in advanced discussions regarding CAPEX investments which we view as a strong validation of the site’s value and strategic fit. While the timeline for full deployment spans several years, we are approaching this expansion with operational discipline and commercial alignment to ensure its success over time.
On pharma sales side, Bora weathered softness in DLS demand in the first quarter but quickly gained market share as a competitor exited in early second quarter. Generic business rebounded in April, supported by strong sales from new 2024 launches including Potassium Chloride ER Tablets (KCL), and anti-angina drugs Diltiazem (DTC and DTS). This recovery underscores Bora’s agility and the resilience of the dual-engine strategy. Furthermore, we have successfully consolidated distribution network for specialty drugs. Bora expects its pediatric spasm product, VIGAFYDE (the 505(b)(2) oral solution), to extend its success in the new patient market into the switch segment in the very near future, supporting future margin and operational leverage expansion.
We continue executing on our goals to scale up, achieve more and integrate smarter, ensuring that both internal and external clients benefit from cost-efficient, regionally aligned manufacturing. By extending the strength of our dual-engine model, we believe Bora shall continue to create above-average total shareholder return.”
1Q2025 Operational Achievements & Full Year Outlook Global CDMO Operations
Global CDMO Operations (excluding internal orders) delivered record-high revenues of NT$1.90 billion in the first quarter, up 52.4% YoY and representing approximately 39% of total revenue. Including internal orders, CDMO revenue reached NT$2.89 billion. A total of 600 million doses were developed and manufactured. Revenue contribution from global top 20 pharmaceutical companies remained steady at approximately 30%, demonstrating strong clientele and advantage of scale. Bora CDMO continues to be a trusted partner for biotech and pharmaceutical innovators.
In 1Q25, the small molecule CDMO pipeline added US$123 million in potential orders and US$78 million in backlog, both marking historic highs.
CAPEX progress across sites reached approximately 50%, focused on debottlenecks, efficiency improvement, capacity increase and infrastructure upgrade to align with client and product needs. Flex Pro line at the Maryland sterile injectable facility was completed ahead of schedule and is expected to begin operations in early Q3.
Maple Grove launched its first CDMO project during the quarter and is currently negotiating with potential clients while evaluating CAPEX plans for differentiated dosage platforms. Overall, North American capacity transformation is progressing as planned.
Large molecule CDMO operation was launched following the January 20 reverse-acquisition of Bora Biologics by Tanvex Biopharm where Bora owns 30.5% of Tanvex. CDMO operations at the San Diego site are now active, and the ongoing 2,000L expansion has received strong interest from late-stage clients. Bora and Tanvex are actively pursuing U.S.-based commercial-scale manufacturing orders with a comprehensive one-stop service model.
Pharma Sales Operations
Pharma Sales Operations revenue reached NT$2.93 billion, representing 82.0% YoY growth and contributing approximately 61% of total revenue based on unadjusted numbers.
As the Upsher-Smith team continue to consolidate distributors for specialty drugs, we saw early signs of positive engagement from both market and payer channels at the end of the first quarter. Following the 2024 integration of TWi, Upsher-Smith and Pyros teams, Bora has established a focused pipeline in CNS specialty areas. The company expects to file its first self-developed 505(b)(2) submission for infantile spasms (Stiripentol) with the U.S. FDA by year-end, alongside other pipeline developments.
Pediatric epilepsy and TSC-related rare diseases represent the first wave of Bora’s pharma sales transformation targets. In addition to reducing over-reliance on generics, high-value rare disease and specialty drugs benefit from strong regulatory and payer support in the specialty pharmacy channel. These markets are less competitive with stable price, and offer targeted access to patient populations, allowing for meaningful long-tail value creation.
Recent Investor Conference
Bora will host an English online earnings call at 7:00 a.m. Taiwan time on May 15, 2025, followed by an investor conference hosted by Taishin Securities at the Grand Hyatt Taipei at 2:00 p.m. on May 16, 2025. Both events will cover the company’s Q1’25 financial and business results and outlook.
The 2025 Annual General Shareholders’ Meeting will be held on May 23 at the Tainan Guantian Industrial Marketing Center.
Bora will participate in the Jefferies Global Healthcare Conference in New York on June 4–5. For 1:1 meetings with management, please contact your Jefferies representative.
Bora 2025 Earnings Schedule
Q2 2025: Expected in the 3rd week of August 2025 Q3 2025: Expected in the 3rd week of November 2025 Q4 2025: Expected in the 2nd week of March 2026
Hashtag: #Bora
The issuer is solely responsible for the content of this announcement.
About Bora
Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients’ quality of life.
By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success “certain,” Bora sets new standards in the pharmaceutical and CDMO industries.
This document and the accompanying information may contain forward-looking statements. All statements regarding the company’s future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company’s control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.
On 13 May, the Xayabouly District Health Office issued a public warning following a series of mushroom poisoning cases that have resulted in six deaths across the province. The urgent notice calls for increased public awareness and preventive measures to avoid further fatalities.